<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7157703\results\search\disease\results.xml">
  <result pre="to come. Interestingly, the most successful LAVs, such as the" exact="smallpox" post="vaccine, the measles vaccine, and the yellow fever vaccine,"/>
  <result pre="the most successful LAVs, such as the smallpox vaccine, the" exact="measles" post="vaccine, and the yellow fever vaccine, have been isolated"/>
  <result pre="such as the smallpox vaccine, the measles vaccine, and the" exact="yellow fever" post="vaccine, have been isolated and/or developed in a purely"/>
  <result pre="history. Smallpox was successfully eradicated in 1980 using the closely-related" exact="vaccinia virus" post="[1], and live measles vaccines averted an estimated 21.1"/>
  <result pre="in 1980 using the closely-related vaccinia virus [1], and live" exact="measles" post="vaccines averted an estimated 21.1 million deaths between 2010"/>
  <result pre="immunity (Table 1) [3]. In contrast, a single dose of" exact="yellow fever" post="vaccine provides protection against the disease for at least"/>
  <result pre="or bacterium that produces mild disease in humans, such as" exact="cowpox" post="for smallpox vaccines [9]. This means that the existence"/>
  <result pre="that produces mild disease in humans, such as cowpox for" exact="smallpox" post="vaccines [9]. This means that the existence of a"/>
  <result pre="stochasticity of evolution. The story of the generation of the" exact="yellow fever" post="vaccine strain 17D strongly supports such reasoning. 17D was"/>
  <result pre="such reasoning. 17D was isolated by serially passaging a virulent" exact="yellow fever" post="virus (YFV) strain in mouse and chicken embryo tissues"/>
  <result pre="popularized by Edward Jenner who demonstrated that inoculation with the" exact="cowpox" post="virus, which only produced mild illness in humans, provided"/>
  <result pre="the 1800s, research by Louis Pasteur with chicken cholera [26]," exact="anthrax" post="[27], and rabies [28] introduced the concept that LAVs"/>
  <result pre="by Louis Pasteur with chicken cholera [26], anthrax [27], and" exact="rabies" post="[28] introduced the concept that LAVs could be generated"/>
  <result pre="an effective way to attenuate pathogens and generate LAVs. The" exact="tuberculosis" post="Bacille Calmette–Guérin (BCG) vaccine was the first vaccine to"/>
  <result pre="the most notable, established LAVs generated this way are the" exact="yellow fever" post="[32], poliovirus [33], measles [34], mumps [35], rubella [36],"/>
  <result pre="generated this way are the yellow fever [32], poliovirus [33]," exact="measles" post="[34], mumps [35], rubella [36], typhoid [37], varicella [38],"/>
  <result pre="way are the yellow fever [32], poliovirus [33], measles [34]," exact="mumps" post="[35], rubella [36], typhoid [37], varicella [38], and zoster"/>
  <result pre="the yellow fever [32], poliovirus [33], measles [34], mumps [35]," exact="rubella" post="[36], typhoid [37], varicella [38], and zoster [39] vaccines."/>
  <result pre="outbreaks in Africa between 2013 and 2016, a recombinant vesicular" exact="stomatitis" post="virus (VSV) expressing the envelope glycoprotein of Ebola virus"/>
  <result pre="rate of 30% [49]. Variolation, or infection with material from" exact="smallpox" post="pustules or scabs, was practiced in China and India"/>
  <result pre="1790s [19,20,21,22,23,24,50]. Although variolation was safer than the contraction of" exact="smallpox" post="itself, it had a 1% chance of mortality even"/>
  <result pre="[9]. While it was commonly known that those who contracted" exact="cowpox" post="(a zoonotic poxvirus closely related to variola that only"/>
  <result pre="what would eventually be termed ‘vaccination’ but issues with using" exact="cowpox" post="as a LAV, which included bacterial contamination and unmeasured"/>
  <result pre="spread of bloodborne diseases [49]. A virus closely related to" exact="cowpox" post="and variola known as vaccinia took the place of"/>
  <result pre="cowpox and variola known as vaccinia took the place of" exact="cowpox" post="as the source of smallpox LAVs by 1900 through"/>
  <result pre="vaccinia took the place of cowpox as the source of" exact="smallpox" post="LAVs by 1900 through what may have also been"/>
  <result pre="varied methods of virus passage [51]. Despite initial setbacks in" exact="smallpox" post="vaccination, vital scientific advancements were made in the 20th"/>
  <result pre="of vaccine preparation), determination of the required potency to induce" exact="smallpox" post="immunity [51], and the introduction of a seed lot"/>
  <result pre="the lack of an animal reservoir for the disease, made" exact="smallpox" post="a prime candidate for global eradication. For these reasons,"/>
  <result pre="Through global effort, and with the aid of effective LAVs," exact="smallpox" post="was eradicated by 1980 [1]. Vaccinia LAVs are potent"/>
  <result pre="and novel zoonotic poxviruses [57,58,59,60] and the potential use of" exact="smallpox" post="in bioterrorism [51], second-generation vaccines such as ACAM2000 [61]"/>
  <result pre="2.2. Generating LAV through Pathogen Attenuation Following Jenner’s success with" exact="smallpox" post="vaccines, Louis Pasteur made strides that initiated a novel"/>
  <result pre="a vaccine from this [26]. He proceeded to produce an" exact="anthrax" post="vaccine in animals, whose etiological agent had been discovered"/>
  <result pre="of inoculation with progressively less dried (and more virulent) samples," exact="rabies" post="could be prevented and treated. In 1885, Pasteur’s attenuated"/>
  <result pre="rabies could be prevented and treated. In 1885, Pasteur’s attenuated" exact="rabies" post="vaccine was successfully administered to a human patient, establishing"/>
  <result pre="TB has been, and still remains, essential to contain this" exact="infectious disease." post="Today, the only licensed TB vaccine available is the"/>
  <result pre="vaccine available is the Bacille Calmette–Guérin (BCG) LAV [67]. M." exact="tuberculosis" post="was first identified by Robert Koch in 1882 [68],"/>
  <result pre="on an infant in 1921 [70]. Apart from an M." exact="tuberculosis" post="contamination that resulted in the Lübeck disaster in 1930,"/>
  <result pre="the eradication of TB is the increasing prevalence of multidrug-resistant" exact="tuberculosis" post="(MDR-TB) and extensively drug-resistant TB (XDR-TB) [65]. Efforts have"/>
  <result pre="have since been made using this method, including vaccines against" exact="yellow fever" post="[32], poliomyelitis [33], measles [34], mumps [35], rubella [36],"/>
  <result pre="made using this method, including vaccines against yellow fever [32]," exact="poliomyelitis" post="[33], measles [34], mumps [35], rubella [36], typhoid [37],"/>
  <result pre="this method, including vaccines against yellow fever [32], poliomyelitis [33]," exact="measles" post="[34], mumps [35], rubella [36], typhoid [37], varicella [38],"/>
  <result pre="including vaccines against yellow fever [32], poliomyelitis [33], measles [34]," exact="mumps" post="[35], rubella [36], typhoid [37], varicella [38], zoster [39],"/>
  <result pre="against yellow fever [32], poliomyelitis [33], measles [34], mumps [35]," exact="rubella" post="[36], typhoid [37], varicella [38], zoster [39], and influenza"/>
  <result pre="[35], rubella [36], typhoid [37], varicella [38], zoster [39], and" exact="influenza" post="[76]. Rotateq, a pentavalent reassortant rotavirus vaccine, was made"/>
  <result pre="was awarded a Nobel Prize for his creation of the" exact="yellow fever" post="LAV [77], and remains the only recipient of such"/>
  <result pre="some of the most well-known LAVs of this category, including" exact="yellow fever," post="measles, polio, and influenza vaccines. Yellow Fever Yellow fever"/>
  <result pre="LAVs of this category, including yellow fever, measles, polio, and" exact="influenza" post="vaccines. Yellow Fever Yellow fever (YF) is a serious"/>
  <result pre="killing thousands at a time [80,81]. YF is caused by" exact="yellow fever" post="virus (YFV), a positive-sense RNA flavivirus, and is transmitted"/>
  <result pre="campaigns in Africa and South America have succeeded in controlling" exact="yellow fever" post="in endemic areas over the past 80 years. However,"/>
  <result pre="is a highly contagious illness produced by the negative-sense RNA" exact="measles" post="virus (MV) of the family Paramyxoviridae, and is transmitted"/>
  <result pre="[90]. Prior to the licensure of a vaccine in 1963," exact="measles" post="epidemics occurred every two to three years and caused"/>
  <result pre="chick embryo fibroblasts at 36–37 °C [9]. The reactogenicity of" exact="measles" post="LAV (MV-LAV) led to the creation of further attenuated"/>
  <result pre="temperatures [92], and passage in human diploid fibroblasts [94]. Independent" exact="measles" post="strains such as CAM 70 [96], Leningrad 4 [97],"/>
  <result pre="[98] were also produced. All MV-LAV cause fevers and a" exact="rash" post="to some extent, but most side effects are mild"/>
  <result pre="on the disease: between 2000 and 2017, the incidence of" exact="measles" post="decreased by 83%, and deaths due to measles fell"/>
  <result pre="incidence of measles decreased by 83%, and deaths due to" exact="measles" post="fell by 80% [99]. Although a potent, cost effective,"/>
  <result pre="many areas of the world. In 2017, 110,000 deaths from" exact="measles" post="were recorded [99], and the incidence of measles has"/>
  <result pre="deaths from measles were recorded [99], and the incidence of" exact="measles" post="has continued to rise. The high communicability of MV"/>
  <result pre="potential to undo decades of work invested into controlling this" exact="infectious disease." post="The Global Vaccine Action Plan aimed to eradicate measles"/>
  <result pre="infectious disease. The Global Vaccine Action Plan aimed to eradicate" exact="measles" post="(and rubella) in five WHO regions by 2020 [100],"/>
  <result pre="highly contagious acute respiratory infection caused by single-stranded RNA segmented" exact="influenza" post="viruses of the Orthomyxovirus family, which are classified into"/>
  <result pre="Orthomyxovirus family, which are classified into four genera known as" exact="influenza" post="A, B, C, and D viruses [76], as well"/>
  <result pre="globe [76], and predisposes individuals to secondary infections such as" exact="pneumonia" post="[113]. Vaccination has been shown to reduce influenza mortality"/>
  <result pre="such as pneumonia [113]. Vaccination has been shown to reduce" exact="influenza" post="mortality and morbidity, but is complicated by antigenic drift"/>
  <result pre="gene segments) and antigenic shift (the emergence of a new" exact="influenza" post="virus subtype by the reassortment of current subtypes) [112,114]."/>
  <result pre="Both inactivated vaccines and LAVs are currently used against the" exact="influenza" post="virus. Trivalent inactivated vaccines (TIVs) are either whole-virus, split"/>
  <result pre="(which contain strain-specific HA and NA antigens). In contrast, live-attenuated" exact="influenza" post="vaccines (LAIVs) are cold-adapted reassortant vaccines made with genes"/>
  <result pre="six additional gene segments from attenuated donor strains [76,112]. The" exact="influenza" post="virus was isolated from the nasal discharge of infected"/>
  <result pre="1933 [115]. This isolation procedure was used to develop inactivated" exact="influenza" post="vaccines, which are grown on the chorio-allantoid membrane of"/>
  <result pre="and subunit inactivated vaccines followed the development of whole-virus inactivated" exact="influenza" post="vaccines in the 1960s and 1970s [118]. These vaccines"/>
  <result pre="and 1970s [118]. These vaccines are used more than whole-virus" exact="influenza" post="vaccines due to their reduced reactogenicity [76]. LAIVs have"/>
  <result pre="from monovalent to trivalent and quadrivalent as new genera of" exact="influenza" post="virus have been discovered [76,118]. The most successful and"/>
  <result pre="2003 [76]. Although TIVs are most frequently used for seasonal" exact="influenza" post="vaccination [76], immunity from subunit TIVs relies on HA"/>
  <result pre="TIVs relies on HA and NA proteins of a specific" exact="influenza" post="strain. In contrast, the inclusion of six viral proteins"/>
  <result pre="contrast, the inclusion of six viral proteins of cold-adapted donor" exact="influenza" post="strains enables LAIV to exhibit heterosubtypic protection, or to"/>
  <result pre="or to improve the viral clearance of different sub-strains of" exact="influenza" post="than the one vaccinated for [112]. However, contraindications due"/>
  <result pre="of LAIV attenuation would assist with the development of new" exact="influenza" post="vaccines that provide longer-lasting immunity and protect against multiple"/>
  <result pre="this reason, the origin of vaccinia, the basis of the" exact="smallpox" post="LAV, is lost to history. Prior to the eradication"/>
  <result pre="of attenuation and immunogenicity. For example, cases of vaccine-derived paralytic" exact="poliomyelitis" post="(VAPP) and increased neurovirulence are associated with mutations in"/>
  <result pre="in the human gastrointestinal tract [125,126]. Interestingly, besides vaccinia virus-derived" exact="smallpox" post="LAV and deliberately reassortant LAIV, LAVs tend to show"/>
  <result pre="vitro, their replication in mouse epithelium differed greatly from wild-type" exact="vaccinia virus," post="and their immunogenic effect was dose-dependent [154]. Other categories"/>
  <result pre="route of administration seems to affect virus protein roles during" exact="vaccinia virus" post="infection [155], or BCG-induced immune responses in NHPs [156]."/>
  <result pre="[195], OPV [189,190], MV-LAV [150,185,197,219,220,221], BCG [156], live-attenuated Venezuelan equine" exact="encephalitis" post="virus [222], YFV-17D [151] or live-attenuated Zika virus [43]."/>
  <result pre="of immunodeficient mouse strains. In 1983, a mouse harboring the" exact="severe combined immunodeficiency" post="(SCID) mutation, a mutation in the Prkdc gene, was"/>
  <result pre="of allogeneic T cell responses by murine myeloid cells) or" exact="anemia" post="(due, for instance, to human macrophages’ activity against murine"/>
  <result pre="were employed to investigate whether long-term passages of an avirulent" exact="measles" post="vaccine strain (Moraten strain) could cause enhanced virulence and"/>
  <result pre="and space. 4.2. Investigating LAV-Induced Immunity in HIS Mice Live-attenuated" exact="influenza" post="vaccines (LAIV) likely represent the LAVs that have been"/>
  <result pre="with autologous T cells prior to vaccination with a trivalent" exact="influenza" post="LAV. Following vaccination, LAIV-CD8+ T cells targeting an HLA-A*0201-restricted"/>
  <result pre="vaccination, LAIV-CD8+ T cells targeting an HLA-A*0201-restricted epitope from the" exact="influenza" post="matrix protein (FluM1) and nonstructural protein 1 were found"/>
  <result pre="mice have been reported to mimic clinical features of human" exact="tuberculosis" post="infection [325]. Following aerosol infection, pulmonary lesions and necrotic"/>
  <result pre="such an infection model to evaluate drug regimens against M." exact="tuberculosis" post="in vivo. In another study, NRG-HIS mice were immunized"/>
  <result pre="BCG vaccine and then challenged four weeks later with M." exact="tuberculosis" post="via the respiratory route. BCG was able to partially"/>
  <result pre="BCG was able to partially protect NRG-HIS mice against M." exact="tuberculosis" post="infection, as demonstrated by a reduced bacterial load and"/>
  <result pre="testing a novel adenoviral-vectored (VV) vaccine expressing an immunodominant M." exact="tuberculosis" post="antigen [326]. The same year, an additional study from"/>
  <result pre="of IFNγ, TNFα and IL-2) in NOG-HIS mice upon M." exact="tuberculosis" post="infection, as well as BCG vaccination prior to M."/>
  <result pre="tuberculosis infection, as well as BCG vaccination prior to M." exact="tuberculosis" post="infection [327]. These authors found evidence of potential T-cell"/>
  <result pre="These authors found evidence of potential T-cell activation upon M." exact="tuberculosis" post="challenge in the lungs, and further suggested that BCG"/>
  <result pre="T-cell activation phenotypes in the same tissue upon subsequent M." exact="tuberculosis" post="infection. However, unlike the previous study, authors did not"/>
  <result pre="that BCG could confer any level of protection against M." exact="tuberculosis" post="in NOG-HIS mice, in contrast to C57BL/6 mice and"/>
  <result pre="shown to be a relevant system to study, for instance," exact="hepatitis" post="B virus infection replication and induced-immune responses [335,336]. The"/>
  <result pre="antibiotic treatment impairs IgA and IgG responses to H1N1 following" exact="influenza" post="vaccination [339], suggesting that particular bacterial species can modulate"/>
  <result pre="Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic" exact="avian influenza" post="viruses, A(H5N1) and A(H7N9)Am. J. Infect. Control.201644e91e10010.1016/j.ajic.2015.11.018 8.GillC.M.BeckhamJ.D.PiquetA.L.TylerK.L.PastulaD.M.Five Emerging"/>
  <result pre="hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian" exact="influenza" post="viruses, A(H5N1) and A(H7N9)Am. J. Infect. Control.201644e91e10010.1016/j.ajic.2015.11.018 8.GillC.M.BeckhamJ.D.PiquetA.L.TylerK.L.PastulaD.M.Five Emerging"/>
  <result pre="Neurol.20193941942710.1055/s-0039-168783931533182 9.MinorP.D.Live attenuated vaccines: Historical successes and current challengesVirology201547937939210.1016/j.virol.2015.03.03225864107 10.FriersonJ.G.The" exact="yellow fever" post="vaccine: A historyYale J. Biol. Med.201083778520589188 11.TheocharidesA.P.RongvauxA.FritschK.FlavellR.A.ManzM.G.Humanized hemato-lymphoid system"/>
  <result pre="effect of prolonged cultivation in vitro upon the pathogenicty of" exact="yellow fever" post="virusJ. Exp. Med.19376576778610.1084/jem.65.6.76719870633 33.SabinA.B.HennessenW.A.WinsserJ.Studies on variants of poliomyelitis virus:"/>
  <result pre="of yellow fever virusJ. Exp. Med.19376576778610.1084/jem.65.6.76719870633 33.SabinA.B.HennessenW.A.WinsserJ.Studies on variants of" exact="poliomyelitis" post="virus: I. Experimental segregation and properties of avirulent variants"/>
  <result pre="from Patients with MeaslesProc. Soc. Exp. Biol. Med.19548627728610.3181/00379727-86-2107313177653 35.BuynakE.B.HillemanM.R.Live attenuated" exact="mumps" post="virus vaccine. 1. Vaccine developmentProc. Soc. Exp. Biol. Med.196612376877510.3181/00379727-123-315994163620"/>
  <result pre="live varicella vaccine (Oka strain)Biken J.19842731366100054 39.OxmanM.LevinM.JohnsonG.SchmaderK.StrausS.GelbL.ArbeitR.SimberkoffM.GershonA.DavisL.A vaccine to prevent" exact="herpes zoster" post="and postherpetic neuralgia in older adultsN. Engl. J. Med.20053522271228410.1056/NEJMoa05101615930418"/>
  <result pre="testis damageNat. Commun.2017867610.1038/s41467-017-00737-828939807 44.EscriouN.CallendretB.LorinV.CombredetC.MarianneauP.FevrierM.TangyF.Protection from SARS coronavirus conferred by live" exact="measles" post="vaccine expressing the spike glycoproteinVirology2014452324110.1016/j.virol.2014.01.00224606680 45.EpsteinJ.E.TewariK.LykeK.E.SimB.K.L.BillingsleyP.F.LaurensM.B.GunasekeraA.ChakravartyS.JamesE.R.SedegahM.et al.Live Attenuated Malaria"/>
  <result pre="48.LiY.CarrollD.S.GardnerS.N.WalshM.C.VitalisE.A.DamonI.K.On the origin of smallpox: Correlating variola phylogenics with historical" exact="smallpox" post="recordsProc. Natl. Acad. Sci. USA20071041578710.1073/pnas.060926810417901212 49.VoigtE.A.KennedyR.B.PolandG.A.Defending against smallpox: A"/>
  <result pre="49.VoigtE.A.KennedyR.B.PolandG.A.Defending against smallpox: A focus on vaccinesExpert Rev. Vaccines2016151197121110.1080/14760584.2016.117530527049653 50.BehbehaniA.M.The" exact="smallpox" post="story: Life and death of an old diseaseMicrobiol. Rev.19834745550910.1128/MMBR.47.4.455-509.19836319980"/>
  <result pre="54.RubinB.A.A note on the development of the bifurcated needle for" exact="smallpox" post="vaccinationWHO Chron.1980341801817376638 55.ConoJ.CaseyC.G.BellD.M.Smallpox vaccination and adverse reactions. Guidance for"/>
  <result pre="reactions. Guidance for cliniciansMMWR Recomm. Rep.200352128 56.PetersenB.W.DamonI.K.PertowskiC.A.Meaney-DelmanD.GuarnizoJ.T.BeigiR.H.EdwardsK.M.FisherM.C.FreyS.E.LynfieldR.et al.Clinical guidance for" exact="smallpox" post="vaccine use in a postevent vaccination programMMWR Recomm. Rep.20156412625695372"/>
  <result pre="and central Africa, 1970–2017Morb. Mortal. Wkly. Rep.20186730610.15585/mmwr.mm6710a529543790 61.NalcaA.ZumbrunE.E.ACAM2000: The new" exact="smallpox" post="vaccine for United States Strategic National StockpileDrug. Des. Dev."/>
  <result pre="clinical study to evaluate the efficacy and safety of CJ" exact="smallpox" post="vaccine in previously vaccinated healthy adultsVaccine2013315239524210.1016/j.vaccine.2013.08.07124021303 63.KennedyJ.S.GreenbergR.N.IMVAMUNE®: Modified vaccinia"/>
  <result pre="healthy adultsVaccine2013315239524210.1016/j.vaccine.2013.08.07124021303 63.KennedyJ.S.GreenbergR.N.IMVAMUNE®: Modified vaccinia Ankara strain as an attenuated" exact="smallpox" post="vaccineExpert Rev. Vaccines20098132410.1586/14760584.8.1.1319093767 64.WilckM.B.SeamanM.S.BadenL.R.WalshS.R.GrandpreL.E.DevoyC.GiriA.KleinjanJ.A.NobleL.C.StevensonK.E.et al.Safety and immunogenicity of modified"/>
  <result pre="trialsClin. Infect. Dis.20145847048010.1093/cid/cit79024336911 74.TrunzB.B.FineP.DyeC.Effect of BCG vaccination on childhood tuberculous" exact="meningitis" post="and miliary tuberculosis worldwide: A meta-analysis and assessment of"/>
  <result pre="Dis.20145847048010.1093/cid/cit79024336911 74.TrunzB.B.FineP.DyeC.Effect of BCG vaccination on childhood tuberculous meningitis and" exact="miliary tuberculosis" post="worldwide: A meta-analysis and assessment of cost-effectivenessLancet20063671173118010.1016/S0140-6736(06)68507-316616560 75.RoyA.EisenhutM.HarrisR.J.RodriguesL.C.SridharS.HabermannS.SnellL.MangtaniP.AdetifaI.LalvaniA.et al.Effect"/>
  <result pre="74.TrunzB.B.FineP.DyeC.Effect of BCG vaccination on childhood tuberculous meningitis and miliary" exact="tuberculosis" post="worldwide: A meta-analysis and assessment of cost-effectivenessLancet20063671173118010.1016/S0140-6736(06)68507-316616560 75.RoyA.EisenhutM.HarrisR.J.RodriguesL.C.SridharS.HabermannS.SnellL.MangtaniP.AdetifaI.LalvaniA.et al.Effect"/>
  <result pre="assessment of cost-effectivenessLancet20063671173118010.1016/S0140-6736(06)68507-316616560 75.RoyA.EisenhutM.HarrisR.J.RodriguesL.C.SridharS.HabermannS.SnellL.MangtaniP.AdetifaI.LalvaniA.et al.Effect of BCG vaccination against Mycobacterium" exact="tuberculosis" post="infection in children: Systematic review and meta-analysisBMJ2014349g464310.1136/bmj.g464325097193 76.collab: World"/>
  <result pre="children: Systematic review and meta-analysisBMJ2014349g464310.1136/bmj.g464325097193 76.collab: World Health OrganizationVaccines against" exact="influenza" post="WHO position paper—November 2012Wkly. Epidemiol. Rec. Relev. Épidémiologique Hebd.201287461476"/>
  <result pre="virus de la fièvre jauneC.R. Acad. Sci.1928186604606 85.TheilerM.SmithH.H.The use of" exact="yellow fever" post="virus modified by in vitro cultivation for human immunizationJ."/>
  <result pre="88.PolandJ.D.CalisherC.H.MonathT.P.DownsW.G.MurphyK.Persistence of neutralizing antibody 30-35 years after immunization with 17D" exact="yellow fever" post="vaccineBull. World Health Organ.1981598959006978196 89.CaseyR.M.HarrisJ.B.Ahuka-MundekeS.DixonM.G.KizitoG.M.NseleP.M.UmutesiG.LavenJ.KosoyO.PalukuG.et al.Immunogenicity of Fractional-Dose Vaccine"/>
  <result pre="of a Highly Attenuated Measles VaccineJAMA Pediatr.196210338638910.1001/archpedi.1962.0208002039804213909753 94.IkicD.BeckM.JuzbasicM.Characterization of Edmonston-Zagreb" exact="measles" post="virusProc. Symposium on Human Diploid CellsYugoslav Academy of Sciences"/>
  <result pre="the Moraten Measles Virus VaccineJAMA196820658759010.1001/jama.1968.031500300430095695578 96.UedaS.TakahashiM.MinekawaY.OginoT.SuzukiN.Studies on further attenuated live" exact="measles" post="vaccine. I. Adaptation of measles virus to the chorioallantoic"/>
  <result pre="96.UedaS.TakahashiM.MinekawaY.OginoT.SuzukiN.Studies on further attenuated live measles vaccine. I. Adaptation of" exact="measles" post="virus to the chorioallantoic membrane of chick embryo and"/>
  <result pre="Reappraisal in the Light of New DataScience1956123115110.1126/science.123.3209.115113337331 103.BodianD.Emerging concept of" exact="poliomyelitis" post="infectionScience195512210510810.1126/science.122.3159.10514385825 104.SabinA.B.WardR.The natural history of human poliomyelitis: I. Distribution"/>
  <result pre="105.PlotkinS.A.OrensteinW.A.OffitP.A.VaccinesElsevier/SaundersAmsterdam, The Netherlands2012 106.NathansonN.KewO.M.From emergence to eradication: The epidemiology of" exact="poliomyelitis" post="deconstructedAm. J. Epidemiol.20101721213122910.1093/aje/kwq32020978089 107.DavisR.BiellikR.Inactivated polio vaccine: Its proposed role"/>
  <result pre="eradicationPan. Afr. Med. J.20131410210.11604/pamj.2013.14.102.258023717717 108.collab: World Health OrganizationGlobal eradication of" exact="poliomyelitis" post="by the year 2000Wkly. Epidemiol. Rec. Relev. épidémiologique Hebd.198863161162"/>
  <result pre="Comparison of the immune response to inactivated and live, attenuated" exact="influenza" post="vaccinesScand. J. Immunol.20045911510.1111/j.0300-9475.2004.01382.x14723616 113.ShresthaS.FoxmanB.BerusJ.Van PanhuisW.G.SteinerC.ViboudC.RohaniP.The role of influenza in"/>
  <result pre="live, attenuated influenza vaccinesScand. J. Immunol.20045911510.1111/j.0300-9475.2004.01382.x14723616 113.ShresthaS.FoxmanB.BerusJ.Van PanhuisW.G.SteinerC.ViboudC.RohaniP.The role of" exact="influenza" post="in the epidemiology of pneumoniaSci. Rep.201551531410.1038/srep1531426486591 114.ArriolaC.GargS.AndersonE.J.RyanP.A.GeorgeA.ZanskyS.M.BennettN.ReingoldA.BargstenM.MillerL.et al.Influenza Vaccination"/>
  <result pre="embryo lungBr. J. Exp. Pathol.194021147 117.StanleyW.The preparation and properties of" exact="influenza" post="virus vaccines concentrated and purified by differential centrifugationJ. Exp."/>
  <result pre="purified by differential centrifugationJ. Exp. Med.19458119321810.1084/jem.81.2.19319871452 118.BarberisI.MylesP.AultS.K.BragazziN.L.MartiniM.History and evolution of" exact="influenza" post="control through vaccination: From the first monovalent vaccine to"/>
  <result pre="Cryophilic Influenza StrainRev. Roum. Inframicrobiol.19652179186 121.MaassabH.Adaptation and growth characteristics of" exact="influenza" post="virus at 25 CNature196721361210.1038/213612a06040602 122.JustewiczD.M.MorinM.J.RobinsonH.L.WebsterR.G.Antibody-forming cell response to virus"/>
  <result pre="to virus challenge in mice immunized with DNA encoding the" exact="influenza" post="virus hemagglutininJ. Virol.1995697712771710.1128/JVI.69.12.7712-7717.19957494280 123.RudenkoL.G.LonskayaN.I.KlimovA.I.VasilievaR.I.RamirezA.Clinical and epidemiological evaluation of a"/>
  <result pre="hemagglutininJ. Virol.1995697712771710.1128/JVI.69.12.7712-7717.19957494280 123.RudenkoL.G.LonskayaN.I.KlimovA.I.VasilievaR.I.RamirezA.Clinical and epidemiological evaluation of a live, cold-adapted" exact="influenza" post="vaccine for 3–14-year-oldsBull. World Health Organ.19967477848653819 124.HerrlichA.MayrA.MahnelH.MunzE.Experimental studies on"/>
  <result pre="polymerase chain reactionVaccine19941250350710.1016/0264-410X(94)90307-78036823 127.HahnC.S.DalrympleJ.M.StraussJ.H.RiceC.M.Comparison of the virulent Asibi strain of" exact="yellow fever" post="virus with the 17D vaccine strain derived from itProc."/>
  <result pre="Natl. Acad. Sci. USA20031007877788210.1073/pnas.113042610012788972 131.BartzR.BrinckmannU.DunsterL.M.RimaB.Ter MeulenV.Schneider-SchauliesJ.Mapping amino acids of the" exact="measles" post="virus hemagglutinin responsible for receptor (CD46) downregulationVirology199622433433710.1006/viro.1996.05388862431 132.SharmaL.B.OhgimotoS.KatoS.KurazonoS.AyataM.TakeuchiK.IharaT.OguraH.Contribution of"/>
  <result pre="matrix, fusion, hemagglutinin, and large protein genes of the CAM-70" exact="measles" post="virus vaccine strain to efficient growth in chicken embryonic"/>
  <result pre="Stimulate Antiviral Immune ResponsesMBio20167e01956-1510.1128/mBio.01956-1526861019 134.LeeE.LobigsM.E protein domain III determinants of" exact="yellow fever" post="virus 17D vaccine strain enhance binding to glycosaminoglycans, impede"/>
  <result pre="virulenceJ. Virol.2008826024603310.1128/JVI.02509-0718400851 135.LefeuvreA.ContaminH.DecelleT.FournierC.LangJ.DeubelV.MarianneauP.Host-cell interaction of attenuated and wild-type strains of" exact="yellow fever" post="virus can be differentiated at early stages of hepatocyte"/>
  <result pre="of hepatocyte infectionMicrobes Infect.200681530153810.1016/j.micinf.2006.01.01316697681 136.WoodsonS.E.HolbrookM.R.Infection of hepatocytes with 17-D vaccine-strain" exact="yellow fever" post="virus induces a strong pro-inflammatory host responseJ. Gen. Virol.2011922262227110.1099/vir.0.031617-021697351"/>
  <result pre="factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by" exact="yellow fever" post="virus infection of hepatocytesVirus Res.201317515515910.1016/j.virusres.2013.04.01323639427 138.WoodsonS.E.FreibergA.N.HolbrookM.R.Differential cytokine responses from"/>
  <result pre="human Kupffer cells following infection with wild-type or vaccine strain" exact="yellow fever" post="virusVirology201141218819510.1016/j.virol.2011.01.01221277609 139.KhaiboullinaS.F.RizvanovA.A.HolbrookM.R.St JeorS.Yellow fever virus strains Asibi and 17D-204"/>
  <result pre="the Sabin Strain of Poliovirus Type 3J. Virol.2004781109710.1128/JVI.78.20.11097-11107.200415452230 142.Barba-SpaethG.LongmanR.S.AlbertM.L.RiceC.M.Live attenuated" exact="yellow fever" post="17D infects human DCs and allows for presentation of"/>
  <result pre="epitopesJ. Exp. Med.20052021179118410.1084/jem.2005135216260489 143.PalmerD.R.FernandezS.BisbingJ.PeachmanK.K.RaoM.BarvirD.GuntherV.BurgessT.KohnoY.PadmanabhanR.et al.Restricted replication and lysosomal trafficking of" exact="yellow fever" post="17D vaccine virus in human dendritic cellsJ. Gen. Virol.20078814815610.1099/vir.0.82272-017170447"/>
  <result pre="human dendritic cellsJ. Gen. Virol.20078814815610.1099/vir.0.82272-017170447 144.BeckA.TeshR.B.WoodT.G.WidenS.G.RymanK.D.BarrettA.D.Comparison of the live attenuated" exact="yellow fever" post="vaccine 17D-204 strain to its virulent parental strain Asibi"/>
  <result pre="Pathog.201612e100578610.1371/journal.ppat.100578627463517 148.MeierK.C.GardnerC.L.KhoretonenkoM.V.KlimstraW.B.RymanK.D.A mouse model for studying viscerotropic disease caused by" exact="yellow fever" post="virus infectionPLoS Pathog.20095e100061410.1371/journal.ppat.100061419816561 149.LamL.K.M.WatsonA.M.RymanK.D.KlimstraW.B.Gamma-interferon exerts a critical early restriction"/>
  <result pre="exerts a critical early restriction on replication and dissemination of" exact="yellow fever" post="virus vaccine strain 17D-204Npj Vaccines2018310.1038/s41541-017-0039-z29387474 150.BankampB.HodgeG.McChesneyM.B.BelliniW.J.RotaP.A.Genetic changes that affect"/>
  <result pre="strain 17D-204Npj Vaccines2018310.1038/s41541-017-0039-z29387474 150.BankampB.HodgeG.McChesneyM.B.BelliniW.J.RotaP.A.Genetic changes that affect the virulence of" exact="measles" post="virus in a rhesus macaque modelVirology2008373395010.1016/j.virol.2007.11.02518155263 151.EngelmannF.JossetL.GirkeT.ParkB.BarronA.DewaneJ.HammarlundE.LewisA.AxthelmM.K.SlifkaM.K.et al.Pathophysiologic and"/>
  <result pre="rhesus macaque modelVirology2008373395010.1016/j.virol.2007.11.02518155263 151.EngelmannF.JossetL.GirkeT.ParkB.BarronA.DewaneJ.HammarlundE.LewisA.AxthelmM.K.SlifkaM.K.et al.Pathophysiologic and transcriptomic analyses of viscerotropic" exact="yellow fever" post="in a rhesus macaque modelPLoS Negl. Trop. Dis.20148e329510.1371/journal.pntd.000329525412185 152.McGoldrickA.MacadamA.J.DunnG.RoweA.BurlisonJ.MinorP.D.MeredithJ.EvansD.J.AlmondJ.W.Role"/>
  <result pre="virus: Mutant generation and animal characterizationJ. Virol.199266261710.1128/JVI.66.5.2617-2630.19921560521 155.TscharkeD.C.ReadingP.C.SmithG.L.Dermal infection with" exact="vaccinia virus" post="reveals roles for virus proteins not seen using other"/>
  <result pre="seen using other inoculation routesJ. Gen. Virol.2002831977198610.1099/0022-1317-83-8-197712124461 156.DarrahP.A.ZeppaJ.J.MaielloP.HackneyJ.A.WadsworthM.H.2ndHughesT.K.PokkaliS.SwansonP.A.2ndGrantN.L.RodgersM.A.et al.Prevention of" exact="tuberculosis" post="in macaques after intravenous BCG immunizationNature20205779510210.1038/s41586-019-1817-831894150 157.NanicheD.YehA.EtoD.ManchesterM.FriedmanR.M.OldstoneM.B.Evasion of host"/>
  <result pre="macaques after intravenous BCG immunizationNature20205779510210.1038/s41586-019-1817-831894150 157.NanicheD.YehA.EtoD.ManchesterM.FriedmanR.M.OldstoneM.B.Evasion of host defenses by" exact="measles" post="virus: Wild-type measles virus infection interferes with induction of"/>
  <result pre="BCG immunizationNature20205779510210.1038/s41586-019-1817-831894150 157.NanicheD.YehA.EtoD.ManchesterM.FriedmanR.M.OldstoneM.B.Evasion of host defenses by measles virus: Wild-type" exact="measles" post="virus infection interferes with induction of alpha/beta interferon productionJ."/>
  <result pre="and increased interferon induction in cells infected with C protein-deficient" exact="measles" post="virusJ. Virol.200680118611186710.1128/JVI.00751-0616987969 159.OhnoS.OnoN.TakedaM.TakeuchiK.YanagiY.Dissection of measles virus V protein in"/>
  <result pre="cells infected with C protein-deficient measles virusJ. Virol.200680118611186710.1128/JVI.00751-0616987969 159.OhnoS.OnoN.TakedaM.TakeuchiK.YanagiY.Dissection of" exact="measles" post="virus V protein in relation to its ability to"/>
  <result pre="and STAT2 phosphorylationFEBS Lett.200354517718210.1016/S0014-5793(03)00528-312804771 161.YokotaS.-i.OkabayashiT.YokosawaN.FujiiN.Growth arrest of epithelial cells during" exact="measles" post="virus infection is caused by upregulation of interferon regulatory"/>
  <result pre="the magnitude of the human CD8 T cell response to" exact="yellow fever" post="vaccinationProc. Natl. Acad. Sci. USA20151123050305510.1073/pnas.150047511225713354 166.AkondyR.S.MonsonN.D.MillerJ.D.EdupugantiS.TeuwenD.WuH.QuyyumiF.GargS.AltmanJ.D.Del RioC.et al.The yellow"/>
  <result pre="yellow fever vaccinationProc. Natl. Acad. Sci. USA20151123050305510.1073/pnas.150047511225713354 166.AkondyR.S.MonsonN.D.MillerJ.D.EdupugantiS.TeuwenD.WuH.QuyyumiF.GargS.AltmanJ.D.Del RioC.et al.The" exact="yellow fever" post="virus vaccine induces a broad and polyfunctional human memory"/>
  <result pre="MostR.G.AkondyR.S.GlidewellJ.T.AlbottS.MasopustD.Murali-KrishnaK.MaharP.L.EdupugantiS.LalorS.et al.Human effector and memory CD8+ T cell responses to" exact="smallpox" post="and yellow fever vaccinesImmunity20082871072210.1016/j.immuni.2008.02.02018468462 168.NomotoA.OmataT.ToyodaH.KugeS.HorieH.KataokaY.GenbaY.NakanoY.ImuraN.Complete nucleotide sequence of the"/>
  <result pre="effector and memory CD8+ T cell responses to smallpox and" exact="yellow fever" post="vaccinesImmunity20082871072210.1016/j.immuni.2008.02.02018468462 168.NomotoA.OmataT.ToyodaH.KugeS.HorieH.KataokaY.GenbaY.NakanoY.ImuraN.Complete nucleotide sequence of the attenuated poliovirus Sabin"/>
  <result pre="from Vaccinia VirusJ. Immunol.19981606249551896 172.HeY.ManischewitzJ.MesedaC.A.MerchlinskyM.VassellR.A.SirotaL.BerkowerI.GoldingH.WeissC.D.Antibodies to the A27 protein of" exact="vaccinia virus" post="neutralize and protect against infection but represent a minor"/>
  <result pre="173.KennedyR.B.PolandG.A.The identification of HLA class II-restricted T cell epitopes to" exact="vaccinia virus" post="membrane proteinsVirology201040823224010.1016/j.virol.2010.09.01320961593 174.ParkinsonJ.E.SmithG.L.Vaccinia Virus Gene A36R Encodes a Mr"/>
  <result pre="and impact on efficacyBMC Genom.2008941310.1186/1471-2164-9-413 176.LewisK.N.LiaoR.GuinnK.M.HickeyM.J.SmithS.BehrM.A.ShermanD.R.Deletion of RD1 from Mycobacterium" exact="tuberculosis" post="Mimics Bacille Calmette-Guérin AttenuationJ. Infect. Dis.200318711712310.1086/34586212508154 177.MattowJ.JungblutP.R.SchaibleU.E.MollenkopfH.-J.LamerS.Zimny-ArndtU.HagensK.MüllerE.-C.KaufmannS.H.E.Identification of proteins"/>
  <result pre="Bacille Calmette-Guérin AttenuationJ. Infect. Dis.200318711712310.1086/34586212508154 177.MattowJ.JungblutP.R.SchaibleU.E.MollenkopfH.-J.LamerS.Zimny-ArndtU.HagensK.MüllerE.-C.KaufmannS.H.E.Identification of proteins from Mycobacterium" exact="tuberculosis" post="missing in attenuated Mycobacterium bovis BCG strainsElectrophoresis2001222936294610.1002/1522-2683(200108)22:14&amp;lt;2936::AID-ELPS2936&amp;gt;3.0.CO;2-S11565788 178.SilB.K.DunsterL.M.LedgerT.N.WillsM.R.MinorP.D.BarrettA.D.Identification of"/>
  <result pre="epitopes that are important in the attenuation process of wild-type" exact="yellow fever" post="virusJ. Virol.199266426510.1128/JVI.66.7.4265-4270.19921376368 179.MiyajimaN.TakedaM.TashiroM.HashimotoK.YanagiY.NagataK.TakeuchiK.Cell tropism of wild-type measles virus is"/>
  <result pre="of wild-type yellow fever virusJ. Virol.199266426510.1128/JVI.66.7.4265-4270.19921376368 179.MiyajimaN.TakedaM.TashiroM.HashimotoK.YanagiY.NagataK.TakeuchiK.Cell tropism of wild-type" exact="measles" post="virus is affected by amino acid substitutions in the"/>
  <result pre="acid substitutions in matrix, fusion and hemagglutinin proteins of wild" exact="measles" post="virus for adaptation to vero cellsIntervirology20115421722810.1159/00031984421228536 181.CondackC.GrivelJ.-C.DevauxP.MargolisL.CattaneoR.Measles Virus Vaccine"/>
  <result pre="of Lymphatic Tissue and Tropism AlterationJ. Infect. Dis.200719654154910.1086/51968917624839 182.DruelleJ.SellinC.I.Waku-KouomouD.HorvatB.WildF.T.Wild type" exact="measles" post="virus attenuation independent of type I IFNVirol. J.200852210.1186/1743-422X-5-2218241351 183.TakedaM.KatoA.KobuneF.SakataH.LiY.ShiodaT.SakaiY.AsakawaM.NagaiY.Measles"/>
  <result pre="of Poliovirus in PrimatesVirology1993192182610.1006/viro.1993.10038390752 191.LuoG.BergmannM.Garcia-SastreA.PaleseP.Mechanism of attenuation of a chimeric" exact="influenza" post="A/B transfectant virusJ. Virol.1992664679468510.1128/JVI.66.8.4679-4685.19921629948 192.WohlgemuthN.YeY.FenstermacherK.J.LiuH.LaneA.P.PekoszA.The M2 protein of live,"/>
  <result pre="A/B transfectant virusJ. Virol.1992664679468510.1128/JVI.66.8.4679-4685.19921629948 192.WohlgemuthN.YeY.FenstermacherK.J.LiuH.LaneA.P.PekoszA.The M2 protein of live, attenuated" exact="influenza" post="vaccine encodes a mutation that reduces replication in human"/>
  <result pre="different Mycobacterium bovis BCG vaccine strainsInfect. Immun.1996641910.1128/IAI.64.1.1-9.19968557324 194.LanthierP.A.HustonG.E.MoquinA.EatonS.M.SzabaF.M.KummerL.W.TigheM.P.KohlmeierJ.E.BlairP.J.BroderickM.et al.Live attenuated" exact="influenza" post="vaccine (LAIV) impacts innate and adaptive immune responsesVaccine2011297849785610.1016/j.vaccine.2011.07.09321816194 195.JegaskandaS.MasonR.D.AndrewsS.F.WheatleyA.K.ZhangR.ReynosoG.V.AmbrozakD.R.SantosC.P.LukeC.J.MatsuokaY.et"/>
  <result pre="Lymph NodesJ. Virol.201892e01970-1710.1128/JVI.01970-1729444938 196.PyoH.-M.ZhouY.Protective efficacy of intranasally administered bivalent live" exact="influenza" post="vaccine and immunological mechanisms underlying the protectionVaccine2014323835384210.1016/j.vaccine.2014.04.06524837774 197.RennickL.J.De VriesR.D.CarsilloT.J.LemonK.Van"/>
  <result pre="neurovirulenceJ. Virol.19946868168810.1128/JVI.68.2.681-688.19948289371 200.ArroyoJ.GuirakhooF.FennerS.ZhangZ.X.MonathT.P.ChambersT.J.Molecular basis for attenuation of neurovirulence of a" exact="yellow fever" post="Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE)J. Virol.20017593494210.1128/JVI.75.2.934-942.200111134306 201.MartyR.R.KnuchelM.C.MorinT.N.NaimH.Y.An immune"/>
  <result pre="basis for attenuation of neurovirulence of a yellow fever Virus/Japanese" exact="encephalitis" post="virus chimera vaccine (ChimeriVax-JE)J. Virol.20017593494210.1128/JVI.75.2.934-942.200111134306 201.MartyR.R.KnuchelM.C.MorinT.N.NaimH.Y.An immune competent mouse"/>
  <result pre="201.MartyR.R.KnuchelM.C.MorinT.N.NaimH.Y.An immune competent mouse model for the characterization of recombinant" exact="measles" post="vaccinesHum. Vaccin. Immunother.201511839010.4161/hv.3435825483519 202.NeiM.XuP.GlazkoG.Estimation of divergence times from multiprotein"/>
  <result pre="a Live Attenuated SIV VaccineAids. Res. Hum. Retrov.2016321125113410.1089/aid.2015.0300 212.VirnikK.HockenburyM.NiY.S.BerenJ.PavlakisG.N.FelberB.K.BerkowerI.Live attenuated" exact="rubella" post="vectors expressing SIV and HIV vaccine antigens replicate and"/>
  <result pre="macaquesRetrovirology2013109910.1186/1742-4690-10-9924041113 213.RoseN.F.MarxP.A.LuckayA.NixonD.F.MorettoW.J.DonahoeS.M.MontefioriD.RobertsA.BuonocoreL.RoseJ.K.An effective AIDS vaccine based on live attenuated vesicular" exact="stomatitis" post="virus recombinantsCell200110653954910.1016/S0092-8674(01)00482-211551502 214.FeldmannH.JonesS.M.Daddario-DiCaprioK.M.GeisbertJ.B.StroherU.GrollaA.BrayM.FritzE.A.FernandoL.FeldmannF.et al.Effective post-exposure treatment of Ebola infectionPLoS"/>
  <result pre="immunity in macaques vaccinated with live attenuated, recombinant, and subunit" exact="measles" post="vaccines in the presence of passively acquired antibodiesJ. Infect."/>
  <result pre="Infect. Dis.199717552453210.1093/infdis/175.3.5249041322 221.LinW.H.GriffinD.E.RotaP.A.PapaniaM.CapeS.P.BennettD.QuinnB.SieversR.E.ShermerC.PowellK.et al.Successful respiratory immunization with dry powder live-attenuated" exact="measles" post="virus vaccine in rhesus macaquesProc. Natl. Acad. Sci. USA20111082987299210.1073/pnas.101733410821282608"/>
  <result pre="aerosol challenge with a virulent IE strain of Venezuelan equine" exact="encephalitis" post="virusVaccine2005233139314710.1016/j.vaccine.2004.12.02315837213 223.BarreiroL.B.MarioniJ.C.BlekhmanR.StephensM.GiladY.Functional comparison of innate immune signaling pathways in"/>
  <result pre="Sci. Alliance2019210.26508/lsa.201900495 225.QuerecT.D.AkondyR.S.LeeE.K.CaoW.NakayaH.I.TeuwenD.PiraniA.GernertK.DengJ.MarzolfB.et al.Systems biology approach predicts immunogenicity of the" exact="yellow fever" post="vaccine in humansNat. Immunol.20091011612510.1038/ni.168819029902 226.GaucherD.TherrienR.KettafN.AngermannB.R.BoucherG.Filali-MouhimA.MoserJ.M.MehtaR.S.DrakeD.R.3rdCastroE.et al.Yellow fever vaccine induces"/>
  <result pre="T-cell memory in individuals vaccinated against polioJ. Virol.2005795988599510.1128/JVI.79.10.5988-5995.200515857985 228.OvsyannikovaI.G.DhimanN.JacobsonR.M.VierkantR.A.PolandG.A.Frequency of" exact="measles" post="virus-specific CD4+ and CD8+ T cells in subjects seronegative"/>
  <result pre="CD8+ T cells in subjects seronegative or highly seropositive for" exact="measles" post="vaccineClin. Diagn. Lab. Immunol.20031041141610.1128/CDLI.10.3.411-416.200312738640 229.BosmaG.C.CusterR.P.BosmaM.J.A severe combined immunodeficiency mutation"/>
  <result pre="or highly seropositive for measles vaccineClin. Diagn. Lab. Immunol.20031041141610.1128/CDLI.10.3.411-416.200312738640 229.BosmaG.C.CusterR.P.BosmaM.J.A" exact="severe combined immunodeficiency" post="mutation in the mouseNature198330152753010.1038/301527a06823332 230.MombaertsP.IacominiJ.JohnsonR.S.HerrupK.TonegawaS.PapaioannouV.E.RAG-1-deficient mice have no mature"/>
  <result pre="hematopoietic engraftment and myeloid differentiationBlood20121192768277710.1182/blood-2011-05-35320122279057 254.ItoR.TakahashiT.KatanoI.KawaiK.KamisakoT.OguraT.Ida-TanakaM.SuemizuH.NunomuraS.RaC.et al.Establishment of a human" exact="allergy" post="model using human IL-3/GM-CSF-transgenic NOG miceJ. Immunol.20131912890289910.4049/jimmunol.120354323956433 255.NicoliniF.E.CashmanJ.D.HoggeD.E.HumphriesR.K.EavesC.J.NOD/SCID mice"/>
  <result pre="expressing human SCF, GM-CSF and IL-3Leukemia2010241785178810.1038/leu.2010.15820686503 261.Feuring-BuskeM.GerhardB.CashmanJ.HumphriesR.K.EavesC.J.HoggeD.E.Improved engraftment of human" exact="acute myeloid leukemia" post="progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in"/>
  <result pre="human SCF, GM-CSF and IL-3Leukemia2010241785178810.1038/leu.2010.15820686503 261.Feuring-BuskeM.GerhardB.CashmanJ.HumphriesR.K.EavesC.J.HoggeD.E.Improved engraftment of human acute" exact="myeloid leukemia" post="progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in"/>
  <result pre="SCF, GM-CSF and IL-3Leukemia2010241785178810.1038/leu.2010.15820686503 261.Feuring-BuskeM.GerhardB.CashmanJ.HumphriesR.K.EavesC.J.HoggeD.E.Improved engraftment of human acute myeloid" exact="leukemia" post="progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in"/>
  <result pre="xenotransplantation into miceNat. Protoc.2017122169218810.1038/nprot.2017.08828933777 300.AntonelliA.NoortW.A.JaquesJ.De BoerB.De Jong-KorlaarR.Brouwers-VosA.Z.Lubbers-AaldersL.Van VelzenJ.F.BloemA.C.YuanH.et al.Establishing human" exact="leukemia" post="xenograft mouse models by implanting human bone marrow-like scaffold-based"/>
  <result pre="stromal cellsStem Cell Res.20141265967210.1016/j.scr.2014.01.00624675053 303.SontakkeP.CarrettaM.JaquesJ.Brouwers-VosA.Z.Lubbers-AaldersL.YuanH.De BruijnJ.D.MartensA.C.VellengaE.GroenR.W.et al.Modeling BCR-ABL and MLL-AF9" exact="leukemia" post="in a human bone marrow-like scaffold-based xenograft modelLeukemia2016302064207310.1038/leu.2016.10827125308 304.MartineL.C.HolzapfelB.M.McGovernJ.A.WagnerF.QuentV.M.HesamiP.WunnerF.M.VaquetteC.De-Juan-PardoE.M.BrownT.D.et"/>
  <result pre="skin transplantation and allograft rejectionTransplantation20108952753610.1097/TP.0b013e3181c9024220134397 311.NadigS.N.WieckiewiczJ.WuD.C.WarneckeG.ZhangW.LuoS.SchiopuA.TaggartD.P.WoodK.J.In vivo prevention of transplant" exact="arteriosclerosis" post="by ex vivo-expanded human regulatory T cellsNat. Med.20101680981310.1038/nm.215420473306 312.McDermottS.P.EppertK.LechmanE.R.DoedensM.DickJ.E.Comparison"/>
  <result pre="HIV-1 variants using bicistronic expression elementsVirology20164889610710.1016/j.virol.2015.11.00426615334 320.IkenoS.SuzukiM.O.MuhsenM.IshigeM.Kobayashi-IshiharaM.OhnoS.TakedaM.NakayamaT.MorikawaY.TeraharaK.et al.Sensitive detection of" exact="measles" post="virus infection in the blood and tissues of humanized"/>
  <result pre="one-step quantitative RT-PCRFront. Microbiol.2013429810.3389/fmicb.2013.0029824130556 321.ValsamakisA.AuwaerterP.G.RimaB.K.KaneshimaH.GriffinD.E.Altered virulence of vaccine strains of" exact="measles" post="virus after prolonged replication in human tissueJ. Virol.1999738791879710.1128/JVI.73.10.8791-8797.199910482633 322.YuC.I.GallegosM.MarchesF.ZurawskiG.RamiloO.Garcia-SastreA.BanchereauJ.PaluckaA.K.Broad"/>
  <result pre="322.YuC.I.GallegosM.MarchesF.ZurawskiG.RamiloO.Garcia-SastreA.BanchereauJ.PaluckaA.K.Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with" exact="influenza" post="virus vaccinesBlood20081123671367810.1182/blood-2008-05-15701618713944 323.YuC.I.BeckerC.WangY.MarchesF.HelftJ.LeboeufM.AnguianoE.PourpeS.GollerK.PascualV.et al.Human CD1c+ dendritic cells drive the"/>
  <result pre="VaccineJ. Infect. Dis.201721613514510.1093/infdis/jix25228531291 327.GroverA.TroyA.RoweJ.TroudtJ.M.CreissenE.McLeanJ.BanerjeeP.FeuerG.IzzoA.A.Humanized NOG mice as a model for" exact="tuberculosis" post="vaccine-induced immunity: A comparative analysis with the mouse and"/>
  <result pre="Infection In VivoMbio2017810.1128/mBio.00819-1728811340 329.ThibodeauxB.A.GarbinoN.C.LissN.M.PiperJ.BlairC.D.RoehrigJ.T.A small animal peripheral challenge model of" exact="yellow fever" post="using interferon-receptor deficient mice and the 17D-204 vaccine strainVaccine2012303180318710.1016/j.vaccine.2012.03.00322425792"/>
  <result pre="17D-204 vaccine strainVaccine2012303180318710.1016/j.vaccine.2012.03.00322425792 330.ShultzL.D.BrehmM.A.BavariS.GreinerD.L.Humanized mice as a preclinical tool for" exact="infectious disease" post="and biomedical researchAnn. N. Y. Acad. Sci.20111245505410.1111/j.1749-6632.2011.06310.x22211979 331.BrehmM.A.JouvetN.GreinerD.L.ShultzL.D.Humanized mice"/>
  <result pre="NOG-pRORγt-γc; RAG, recombination activating genes; SCF, stem cell factor; SCID," exact="severe combined immunodeficiency;" post="SGM3, stem cell factor, granulocyte-macrophage colony-stimulating factor, and interleukin-3;"/>
  <result pre="been investigated with, and are codenamed as follows: MV, live-attenuated" exact="measles" post="virus; HIV, live-attenuated human immunodeficiency virus; YFV, live-attenuated yellow"/>
  <result pre="live-attenuated measles virus; HIV, live-attenuated human immunodeficiency virus; YFV, live-attenuated" exact="yellow fever" post="virus; IV, live-attenuated influenza virus; BCG, Tuberculosis Bacille Calmette-Guérin"/>
  <result pre="human immunodeficiency virus; YFV, live-attenuated yellow fever virus; IV, live-attenuated" exact="influenza" post="virus; BCG, Tuberculosis Bacille Calmette-Guérin vaccine. For each model"/>
  <result pre="NOD/shi-SCID-IL2Rγnull; NOJ, NOD-SCID JAK3null; NRG, NOD- RAG1−/−IL2Rγnull; NSG, NOD/LtSz-SCID-IL2Rγnull; SCID," exact="severe combined immunodeficiency." post="Figure 3 Enhancing human immune system mice for LAV"/>
  <result pre="parental strain or a virulent strain (with the exception of" exact="smallpox" post="and influenza LAVs), (ii) studies on mechanisms governing LAV"/>
  <result pre="or a virulent strain (with the exception of smallpox and" exact="influenza" post="LAVs), (ii) studies on mechanisms governing LAV attenuation performed"/>
 </snippets>
</snippetsTree>
